Search
Search titles only
By:
Search titles only
By:
Home
Forums
New posts
Search forums
What's new
New posts
New profile posts
Latest activity
Members
Current visitors
New profile posts
Search profile posts
Log in
Register
Search
Search titles only
By:
Search titles only
By:
New posts
Search forums
Menu
Install the app
Install
Reply to Thread
Guest, we'd love to know what you think about the forum! Take the
Diabetes Forum Survey 2025 »
Home
Forums
Diabetes News and Research
Diabetes News
NICE recommends dapagliflozin for triple therapy in type 2 diabetes
JavaScript is disabled. For a better experience, please enable JavaScript in your browser before proceeding.
You are using an out of date browser. It may not display this or other websites correctly.
You should upgrade or use an
alternative browser
.
Message
<blockquote data-quote="DCUK NewsBot" data-source="post: 1314711" data-attributes="member: 106455"><p>New guidelines from the National Institute for Health and Care Excellence (NICE) recommend that Forxiga (dapagliflozin) should be used treat type 2 diabetes as part of "triple therapy". Forxiga, an SGLT2 inhibitor which works by helping the kidneys remove excess glucose through urine - lowering blood glucose levels - has been recommended as a third drug when two current type 2 diabetes drugs are not improving a patient's blood glucose levels. Professor Carole Longson, director of the NICE centre for health technology evaluation, said: "Having a range of drug options makes it easier to tailor treatments for type 2 diabetes to each person's individual needs. "This new guidance recommends dapagliflozin in triple therapy - only in combination with metformin and a sulphonylurea - which will widen the choice available for people whose diabetes isn&#146;t well controlled with two drugs." People with type 2 diabetes are often offered metformin as a first-line treatment alongside diet and exercise. But if this fails to improve their diabetes management, a second or even third drug might be added. Prior to these guidelines, Jardiance (empagliflozin) and Invokana (canagliflozin) had been recommended by NICE as options for triple therapy. These drugs are also SGLT2 inhibitors and are already recommended for use as monotherapy if a person can't tolerate metformin or other specific drugs, or in dual therapy with metformin. Longson added: "As we've been able to publish this final guidance sooner because of positive draft recommendations, we hope that people who need this extra treatment option will benefit more quickly." People struggling to control their blood glucose levels with medication can achieve greater diabetes control by eating a low-carb diet. Our Low Carb Program has helped people to improve their diabetes control, lose weight and reduce their dependence on medication.</p><p></p><p><a href="http://www.diabetes.co.uk/news/2016/nov/nice-recommends-dapagliflozin-for-triple-therapy-in-type-2-diabetes-95359168.html" target="_blank">Continue reading...</a></p></blockquote><p></p>
[QUOTE="DCUK NewsBot, post: 1314711, member: 106455"] New guidelines from the National Institute for Health and Care Excellence (NICE) recommend that Forxiga (dapagliflozin) should be used treat type 2 diabetes as part of "triple therapy". Forxiga, an SGLT2 inhibitor which works by helping the kidneys remove excess glucose through urine - lowering blood glucose levels - has been recommended as a third drug when two current type 2 diabetes drugs are not improving a patient's blood glucose levels. Professor Carole Longson, director of the NICE centre for health technology evaluation, said: "Having a range of drug options makes it easier to tailor treatments for type 2 diabetes to each person's individual needs. "This new guidance recommends dapagliflozin in triple therapy - only in combination with metformin and a sulphonylurea - which will widen the choice available for people whose diabetes isn’t well controlled with two drugs." People with type 2 diabetes are often offered metformin as a first-line treatment alongside diet and exercise. But if this fails to improve their diabetes management, a second or even third drug might be added. Prior to these guidelines, Jardiance (empagliflozin) and Invokana (canagliflozin) had been recommended by NICE as options for triple therapy. These drugs are also SGLT2 inhibitors and are already recommended for use as monotherapy if a person can't tolerate metformin or other specific drugs, or in dual therapy with metformin. Longson added: "As we've been able to publish this final guidance sooner because of positive draft recommendations, we hope that people who need this extra treatment option will benefit more quickly." People struggling to control their blood glucose levels with medication can achieve greater diabetes control by eating a low-carb diet. Our Low Carb Program has helped people to improve their diabetes control, lose weight and reduce their dependence on medication. [url="http://www.diabetes.co.uk/news/2016/nov/nice-recommends-dapagliflozin-for-triple-therapy-in-type-2-diabetes-95359168.html"]Continue reading...[/url] [/QUOTE]
Verification
Post Reply
Home
Forums
Diabetes News and Research
Diabetes News
NICE recommends dapagliflozin for triple therapy in type 2 diabetes
Top
Bottom
Find support, ask questions and share your experiences. Ad free.
Join the community »
This site uses cookies. By continuing to use this site, you are agreeing to our use of cookies.
Accept
Learn More.…